Results 51 to 60 of about 63,359 (335)

IDH1 Non-Canonical Mutations and Survival in Patients with Glioma

Diagnostics, 2021
Background: Non-canonical mutations of the isocitrate dehydrogenase (IDH) genes have been described in about 20–25% and 5–12% of patients with WHO grade II and III gliomas, respectively.
Enrico Franceschi, Dario De Biase, Vincenzo Di Nunno, Annalisa Pession, Alicia Tosoni, Lidia Gatto, Giovanni Tallini, Michela Visani, Raffaele Lodi, Stefania Bartolini, Alba Ariela Brandes   +10 more
doaj   +1 more source

Acute myeloid leukemia with IDH1 and IDH2 mutations: 2021 treatment algorithm

Blood Cancer Journal, 2021
Acute myeloid leukemia is a genetically heterogeneous hematologic malignancy; approximately 20% of AML harbors a mutation in the isocitrate dehydrogenase (IDH) genes, IDH1 or IDH2. These recurrent mutations in key metabolic enzymes lead to the production
G. Issa, C. Dinardo
semanticscholar   +1 more source

Single-center, observational study of AML/MDS-EB with IDH1/2 mutations: genetic profile, immunophenotypes, mutational kinetics and outcomes

Hematology, 2023
Objective IDH1/2 mutations, intervening in epigenetic procedures, are frequently encountered in acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS).
Vasiliki Papadopoulou, Jacqueline Schoumans, Valentin Basset, Françoise Solly, Jérôme Pasquier, Sabine Blum, Olivier Spertini   +6 more
doaj   +1 more source

Multiscale, multimodal analysis of tumor heterogeneity in IDH1 mutant vs wild-type diffuse gliomas. [PDF]

, 2019
Glioma is recognized to be a highly heterogeneous CNS malignancy, whose diverse cellular composition and cellular interactions have not been well characterized. To gain new clinical- and biological-insights into the genetically-bifurcated IDH1 mutant (mt)
Adkins, Jonathan, Al-Kofahi, Yousef, Barnholtz-Sloan, Jill S, Berens, Michael E, Byron, Sara A, Cho, Sanghee, Couce, Marta, Cuyugan, Lori, Devine, Karen, Dinn, Sean, Ginty, Fiona, Graf, John F, Halperin, Rebecca F, Kiefer, Jeffrey, Kim, Seungchan, Liang, Winnie S, McDonough, Elizabeth, Nasser, Sara, Nelson, Sarah J, Ostrom, Quinn, Phillips, Joanna J, Prados, Michael, Rusu, Mirabela, Schyberg, Shannon, Sloan, Andrew E, Sood, Anup, Wolansky, Leo, Zavodszky, Maria I   +27 more
core   +1 more source

Dysregulated Lipid Synthesis by Oncogenic IDH1 Mutation Is a Targetable Synthetic Lethal Vulnerability

Cancer Discovery, 2022
Synthetic lethality and mass spectrometry were used to identify novel metabolic vulnerabilities in cancers with IDH1, but not IDH2, mutations that are targetable in the setting of ivosidenib resistance.
Daniel Thomas, Manhong Wu, Y. Nakauchi, M. Zheng, Chloe A L Thompson-Peach, Kelly Lim, N. Landberg, T. Köhnke, N. Robinson, Satinder Kaur, M. Kutyna, M. Stafford, D. Hiwase, A. Reinisch, G. Peltz, R. Majeti   +15 more
semanticscholar   +1 more source

Molecular and Genetic Determinants of Glioma Cell Invasion. [PDF]

, 2017
A diffusely invasive nature is a major obstacle in treating a malignant brain tumor, "diffuse glioma", which prevents neurooncologists from surgically removing the tumor cells even in combination with chemotherapy and radiation.
Kato, Yoichiro, Masui, Kenta, Mischel, Paul S, Sawada, Tatsuo, Shibata, Noriyuki   +4 more
core   +5 more sources

Metabolic Profiling of IDH Mutation and Malignant Progression in Infiltrating Glioma. [PDF]

, 2017
Infiltrating low grade gliomas (LGGs) are heterogeneous in their behavior and the strategies used for clinical management are highly variable. A key factor in clinical decision-making is that patients with mutations in the isocitrate dehydrogenase 1 and ...
Berger, Mitchel S, Chang, Susan M, Crane, Jason C, Elkhaled, Adam, Jalbert, Llewellyn E, Kurhanewicz, John, Molinaro, Annette M, Neill, Evan, Nelson, Sarah J, Olson, Marram P, Phillips, Joanna J, Ronen, Sabrina M, Williams, Aurelia   +12 more
core   +1 more source

AMPLIFY-NEOVAC: a randomized, 3-arm multicenter phase I trial to assess safety, tolerability and immunogenicity of IDH1-vac combined with an immune checkpoint inhibitor targeting programmed death-ligand 1 in isocitrate dehydrogenase 1 mutant gliomas

Neurological Research and Practice, 2022
Introduction Isocitrate dehydrogenase (IDH) mutations are disease-defining mutations in IDH-mutant astrocytomas and IDH-mutant and 1p/19q-codeleted oligodendrogliomas.
L. Bunse, Anne-Kathleen Rupp, I. Poschke, T. Bunse, K. Lindner, A. Wick, Jens Blobner, M. Misch, G. Tabatabai, M. Glas, O. Schnell, J. Gempt, M. Denk, G. Reifenberger, M. Bendszus, P. Wuchter, J. Steinbach, W. Wick, M. Plattén   +18 more
semanticscholar   +1 more source

IDH1 R132H Mutation Enhances Cell Migration by Activating AKT-mTOR Signaling Pathway, but Sensitizes Cells to 5-FU Treatment as NADPH and GSH Are Reduced. [PDF]

PLoS ONE, 2017
Mutations of isocitrate dehydrogenase 1 and 2 (IDH1 and IDH2) gene were recently discovered in vast majority of World Health Organization (WHO) grade II/III gliomas.
Huixia Zhu, Ye Zhang, Jianfeng Chen, Jiangdong Qiu, Keting Huang, Mindan Wu, Chunlin Xia   +6 more
doaj   +1 more source

Acute Myeloid Leukemia [PDF]

, 2017
Acute myeloid leukemia (AML) is the most common type of leukemia. The Cancer Genome Atlas Research Network has demonstrated the increasing genomic complexity of acute myeloid leukemia (AML).
Fortina, P, Kricka, Lj, Londin, E, Park, Jy   +3 more
core   +1 more source